Gnubiotics into Preclinical Collaboration with NIAID/NIH to Evaluate the Potential of Glycopeptide candidates For Treatment of Multi-Drug Resistance (MDR) Infections.
Gnubiotics Sciences SA (Gnubiotics), a Swiss biotech company pioneering novel microbiome targeted solutions for humans and companion animals, has signed a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the potential of its pipeline glycopeptide candidates (GCX) for the treatment of multidrug-resistant (MDR) infections.
The company is developing its platform of microbiome targeting glycopeptides for the potential treatment of carbapenem–resistant Enterobacterales ( CRE), , Vancomycin Resistant Enterococcus (VRE) and multi-drug resistant (MDR) Pseudomonas. aeruginosa through an alternative mechanism of preventing bacterial colonization and infections. CRE, VRE and MDR P. aeruginosa which are all recognized as urgent and serious antibiotic resistance threats by the US Centers for Disease Control (CDC) are major concerns for patients in healthcare facilities and the community with about 15’000 deaths in 2017 in US alone. Colonization of the gut by these bacteria often preceed systemic infection. Unfortunately however, antibiotics often increase susceptibility to systemic infections by disrupting the protective microbiome.
Gnubiotics glycan platform has already shown positive results in mouse models of Clostridium Difficile (C. Diff) infection, specifically accelerating gut microbiome restoration post antibiotics administration while also showing a statistically relevant preventing re-colonization by C Diff.
Gnubiotics will be utilizing the non-clinical and pre-clinical services program offered by the National Institute of Allergy and Infectious Diseases. NIAID will be responsible for studies conducted under the NCEA.
Previously, Gnubiotics presented its programs and capabilities to the US Biomedical Advanced Research Authority (BARDA) through a BARDA TechWatch. Discussions with NIAID was initiated following a review of program and recommendation by BARDA.